Scilex Holding (SCLXW) Non-Current Debt (2021 - 2025)
Scilex Holding (SCLXW) recorded quarterly Non-Current Debt of $22.5 million in Q4 2025, up 2560.36% quarter-over-quarter from $845000.0 in Q4 2024, and up 2560.36% on a YoY basis from $845000.0 in Q4 2024.
Scilex Holding (SCLXW) Non-Current Debt (2021 - 2025) Analysis & Trends
Scilex Holding's Non-Current Debt history runs 5 years deep, the most recent figure standing at $22.5 million for Q4 2025.
- In Q4 2025, Non-Current Debt rose 2560.36% year-over-year to $22.5 million; the TTM figure through Dec 2025 stood at $22.5 million (up 2560.36% YoY), while the FY2025 annual figure was $22.5 million, up 2560.36% from the prior year.
- Non-Current Debt was $22.5 million for Q4 2025 at Scilex Holding, up from $845000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $72.0 million in Q4 2021 to a low of $845000.0 in Q4 2024.
- Historically, Non-Current Debt has averaged $18.4 million across 5 years, with a median of $15.3 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt tumbled 95.04% in 2024, then jumped 2560.36% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $72.0 million in 2021, then tumbled by 95.87% to $3.0 million in 2022, then surged by 473.35% to $17.0 million in 2023, then sank by 95.04% to $845000.0 in 2024, then surged by 2560.36% to $22.5 million in 2025.
- The last three Non-Current Debt figures came in at $22.5 million (Q4 2025), $845000.0 (Q4 2024), and $14.3 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.48 Mn |
| Dec 31, 2025 | 22.48 Mn |
| Dec 31, 2024 | 845,000.00 |
| Dec 31, 2024 | 845,000.00 |
| Sep 30, 2024 | 14.33 Mn |
| Sep 30, 2024 | 14.33 Mn |
| Jun 30, 2024 | 29.03 Mn |
| Jun 30, 2024 | 29.03 Mn |
| Mar 31, 2024 | 16.32 Mn |
| Mar 31, 2024 | 16.32 Mn |
| Dec 31, 2023 | 17.04 Mn |
| Dec 31, 2023 | 17.04 Mn |
| Sep 30, 2023 | 6.93 Mn |
| Sep 30, 2023 | 6.93 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Dec 31, 2021 | 72.04 Mn |
| Dec 31, 2021 | 72.04 Mn |